Clinical Chemistry Siemens Point of Care - Urinalysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 1546-1551, 2006. First published June 15, 2006; 10.1373/clinchem.2006.067041
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2006.067041v1
52/8/1546    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Slagter, M. H.
Right arrow Articles by Diamandis, E. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Slagter, M. H.
Right arrow Articles by Diamandis, E. P.
Related Collections
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2006;52:1546-1551.)
© 2006 American Association for Clinical Chemistry, Inc.

Endocrinology and Metabolism

Effect of Testosterone Administration on Serum and Urine Kallikrein Concentrations in Female-to-Male Transsexuals

Margrita H. Slagter1, Andreas Scorilas2, Louis J.G. Gooren1, Willem de Ronde1, Antoninus Soosaipillai3, Erik J. Giltay4, Miltiadis Paliouras3,5 and Eleftherios P. Diamandis3,5,a

1 Department of Endocrinology, Vrije Universiteit University Medical Centre, Amsterdam, The Netherlands.
2 Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Athens, Athens, Greece.
3 Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada.
4 Geestelijke Gezondheidszorg Delfland, Institute of Mental Health, Delft, The Netherlands.
5 Department of Laboratory Medicine and Pathobiology, University of Toronto, ON, Canada.

aAddress correspondence to this author at: Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Ave., Toronto, Ontario, Canada M5G 1X5, Fax 416-586-8628; e-mail ediamandis{at}mtsinai.on.ca.

Background: Concentrations of human tissue kallikreins (hKs), a group of 15 secreted serine proteases found in many tissues, are modulated by steroid hormones in cancer cell lines. To gain insight into in vivo kallikrein regulation we measured kallikrein concentrations in serum and urinary tissue in female-to-male transsexuals before and after testosterone administration.

Methods: We collected blood and urine samples before treatment and after 4 and 12 months from 28 female-to-male transsexuals who received 250 mg of testosterone esters intramuscularly every 2 weeks. We used ELISA assays to measure multiple kallikreins in serum and urine.

Results: After testosterone administration, serum testosterone concentrations increased by ~15-fold. Serum kallikrein concentrations increased dramatically for hK3 (prostate-specific antigen) and increased moderately for hK2, hK5, hK6, hK7, hK8, hK10, and hK11. In urine, we noted major increases for hK3 and hK2 only. For all other kallikrein concentrations, we observed no considerable changes.

Conclusions: We conclude that, in serum and urine of female-to-male transsexuals after testosterone administration, hK3 (prostate-specific antigen) and to a lesser extent hK2 concentrations increase dramatically, but concentration of other kallikreins increase either moderately in serum (hK5, hK6, hK7, hK8, hK10, and hK11) or not at all in either serum (hK4, hK13, hK14) or urine (hK4, hK5, hK6, hK7, hK8, hK10, hK11, hK13, hK14).




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Clin. Endocrinol. Metab.Home page
A. Mueller, F. Kiesewetter, H. Binder, M. W. Beckmann, and R. Dittrich
Long-Term Administration of Testosterone Undecanoate Every 3 Months for Testosterone Supplementation in Female-to-Male Transsexuals
J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3470 - 3475.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.